CRISPR Therapeutics AG (LON:0VRQ)

CRISPR Therapeutics AG Statistics

Total Valuation

LON:0VRQ has a market cap or net worth of GBP 4.07 billion. The enterprise value is 2.77 billion.

Market Cap	4.07B
Enterprise Value	2.77B

Important Dates

The next estimated earnings date is Wednesday, February 11, 2026.

Earnings Date	Feb 11, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	95.30M
Shares Outstanding	n/a
Shares Change (YoY)	+5.48%
Shares Change (QoQ)	+4.86%
Owned by Insiders (%)	0.52%
Owned by Institutions (%)	74.83%
Float	94.80M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	142.65
PB Ratio	2.85
P/TBV Ratio	2.85
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-7.62
EV / Sales	96.19
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.27

Financial Position

The company has a current ratio of 16.22, with a Debt / Equity ratio of 0.11.

Current Ratio	16.22
Quick Ratio	16.10
Debt / Equity	0.11
Debt / EBITDA	n/a
Debt / FCF	-0.70
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -25.33% and return on invested capital (ROIC) is -13.92%.

Return on Equity (ROE)	-25.33%
Return on Assets (ROA)	-13.28%
Return on Invested Capital (ROIC)	-13.92%
Return on Capital Employed (ROCE)	-22.49%
Revenue Per Employee	72,571
Profits Per Employee	-924,335
Employee Count	393
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

In the past 12 months, LON:0VRQ has paid 2.77 million in taxes.

Income Tax	2.77M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +14.03% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+14.03%
50-Day Moving Average	61.23
200-Day Moving Average	50.52
Relative Strength Index (RSI)	51.09
Average Volume (20 Days)	5,949

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.07

Income Statement

In the last 12 months, LON:0VRQ had revenue of GBP 28.52 million and -363.26 million in losses. Loss per share was -4.15.

Revenue	28.52M
Gross Profit	-320.39M
Operating Income	-355.71M
Pretax Income	-360.50M
Net Income	-363.26M
EBITDA	-341.83M
EBIT	-355.71M
Loss Per Share	-4.15

Balance Sheet

The company has 1.43 billion in cash and 156.99 million in debt, giving a net cash position of 1.29 billion.

Cash & Cash Equivalents	1.43B
Total Debt	156.99M
Net Cash	1.29B
Net Cash Per Share	n/a
Equity (Book Value)	1.43B
Book Value Per Share	15.18
Working Capital	1.35B

Cash Flow

In the last 12 months, operating cash flow was -225.04 million and capital expenditures -484,305, giving a free cash flow of -225.52 million.

Operating Cash Flow	-225.04M
Capital Expenditures	-484,305
Free Cash Flow	-225.52M
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	-1,247.21%
Pretax Margin	-1,263.99%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

LON:0VRQ does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.48%
Shareholder Yield	-5.48%
Earnings Yield	-8.93%
FCF Yield	-5.54%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0VRQ has an Altman Z-Score of 6.63 and a Piotroski F-Score of 1.

Altman Z-Score	6.63
Piotroski F-Score	1